News & Events August

August New Hires & Promotions

August 31, 2020

CTI welcomes all the new employees who have recently joined the team, and congratulates the employees who have recently received a promotion! Joanna Brown joins as Clinical Research Associate II Carmen Cespedes Cevasco joins as Senior Clinical Research Associate Emily Crawford joins as Senior Clinical Research Associate Barbara McCarty ...

Read More

Consistent Quality Regulation Allows for Multiple COVID-19 Related EUAs

August 31, 2020

As we enter into the ninth month of the COVID-19 pandemic, new SARS-Cov-2 infections continue to occur, both at home in the United States and abroad. World leaders, global health organizations, national and state ...

Read More

CTI and Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 Clinical Trial

August 13, 2020

FOR IMMEDIATE RELEASE [Covington, KY] August 13, 2020 – CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization, and Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focusing on the development of therapeutic drugs for the treatment ...

Read More

CTI and Arcturus Therapeutics Announce Initiation of Dosing of COVID-19 Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 Study

August 11, 2020

Potential for highly differentiated COVID-19 vaccine profile with a single administration, at a low dose Clinical study data expected in Q4 2020 FOR IMMEDIATE RELEASE [San Diego, CA and Covington, KY, August 11, 2020] –Arcturus Therapeutics Holdings Inc. (the “Company”, ...

Read More

CTI and Humanigen Expand Phase III Study of Lenzilumab in COVID-19 to Brazil

August 10, 2020

FOR IMMEDIATE RELEASE [Burlingame, CA and Covington, KY, August 10, 2020 ]– Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, ...

Read More

Angion Enrolls First Patients in Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

August 4, 2020

FOR IMMEDIATE RELEASE [San Francisco, CA and Covington, KY, August 4, 2020 ] – Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, ...

Read More

Subscribe to our mailing list

* indicates required